AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hostetler, K. Y.
Right arrow Articles by Beadle, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hostetler, K. Y.
Right arrow Articles by Beadle, J. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2006, p. 2857-2859, Vol. 50, No. 8
0066-4804/06/$08.00+0     doi:10.1128/AAC.01223-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Alkoxyalkyl Esters of (S)-9-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]Adenine Are Potent Inhibitors of the Replication of Wild-Type and Drug-Resistant Human Immunodeficiency Virus Type 1 In Vitro

Karl Y. Hostetler,* Kathy A. Aldern, William B. Wan, Stephanie L. Ciesla, and James R. Beadle

Department of Medicine, Division of Infectious Disease, University of California, San Diego, and Veterans Medical Research Foundation, La Jolla, California

Received 19 September 2005/ Returned for modification 9 November 2005/ Accepted 8 May 2006


   ABSTRACT
Top
 Abstract
Text
 References
 
(S)-9-[3-Hydroxy-2-(phosphonomethoxy)propyl]adenine [(S)-HPMPA], is an effective broad-spectrum antiviral against many DNA viruses but has been reported to be inactive against human immunodeficiency virus (HIV). We synthesized several alkoxyalkyl esters of (S)-HPMPA and now report that hexadecyloxypropyl-(S)-HPMPA [HDP-(S)-HPMPA] and octadecyloxyethyl-(S)-HPMPA [ODE-(S)-HPMPA]had 50% effective concentrations of 0.4 to 7.0 nanomolar and were nearly fully active against HIV variants having reverse transcriptase mutations M184V and K103N and against a zidovudine-resistant variant with mutations D67N, K70R, T215Y, and K219Q. Resistance to HDP-(S)-HPMPA and ODE-(S)-HPMPA was noted for a mutant with mutation K65R. HDP-(S)-HPMPA is also active against herpes simplex virus type 1, human cytomegalovirus, hepatitis B virus, adenoviruses, and orthopoxviruses and is worthy of further evaluation as a possibly therapy for HIV infection.


   TEXT
Top
 Abstract
 Text
References
 
9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]adenine [(S)-HPMPA] was first synthesized and evaluated as an antiviral by De Clercq et al. in 1986 (9, 13) and was shown to inhibit replication of many double-stranded DNA viruses, including herpes simplex virus, human cytomegalovirus, varicella-zoster virus, Epstein-Barr virus, and adenoviruses (10) and various orthopoxviruses, including vaccinia, cowpox, monkeypox, and variola viruses (2, 14, 15). However, numerous studies indicate that (S)-HPMPA lacks antiviral activity against RNA viruses and retroviruses, including human immunodeficiency virus type 1 (HIV-1) (3, 8, 13, 17).

Our group reported previously that conversion of acyclic nucleoside phosphonates to alkoxyalkyl or alkyl esters greatly increases their antiviral activity (4, 16), and structure-activity studies have established that the optimal length of the alkoxyalkyl ester is about 20 atoms (20). Alkoxyalkyl esters of cidofovir (CDV) are orally active in lethal infection models with ectromelia (6) and cowpox and vaccinia (18). To evaluate this approach with (S)-HPMPA, we synthesized a series of alkoxyalkyl esters of (S)-HPMPA and tested them against HIV-1 infection in MT-2 cells. We now report that alkoxyalkyl esters of (S)-HPMPA are active against HIV-1 in the low-nanomolar range, while (S)-HPMPA itself has essentially no activity, as reported previously.

(Portions of this paper were presented in abstract form at the International Conference on Antiviral Research, 11 to 14 April 2005, Barcelona, Spain.)

The route of synthesis of the (S)-HPMPA alkoxyalkyl esters is shown in Fig. 1. Details of the synthesis, purification, and purity (>98%) have been reported elsewhere (5). MT-2 cells (AIDS Research and Reference Reagent Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health) were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, Kans.), 10 mM HEPES buffer, 50 IU of penicillin/ml, and 50 µg of streptomycin/ml. HIV-1LAI and HIV variants M184V, K65R, and K103N were obtained from the AIDS Research and Reference Reagent Program. Zidovudine (AZT)-resistant HIV-1 with four mutations (D67N, K70R, T215Y, and K219Q) in the reverse transcriptase (4xAZT) was kindly provided by Douglas D. Richman of the University of California, San Diego.


Figure 1
View larger version (7K):
[in this window]
[in a new window]
  		FIG. 1. Synthesis of alkoxyalkyl esters of (S)-HPMPA. Reagents and conditions: step a, diethyl p-toluenesulfonyloxymethylphosphonate and trimethylsilyl bromide followed by oxalyl chloride; step b, NaH and triethylamine, 60°C; step c, 80% aqueous acetic acid.

 
The antiviral activity of each compound was determined by inoculating MT-2 cells with HIV-1LAI at a multiplicity of infection of 0.001 50% tissue culture infective dose/cell, followed by incubation in the presence of threefold serial drug dilutions (three wells per dilution) as previously described (11). Four days after infection, culture supernatants were harvested, lysed with 0.5% Triton X-100, and assayed for p24 antigen concentration by using a commercial enzyme-linked immunosorbent assay (Perkin-Elmer Life Sciences, Boston, MA). The antiviral activity of each compound is expressed as the 50% effective concentration (EC50), which is the concentration required to inhibit p24 antigen production by 50%. To assess cytotoxicity, MT-2 cells were incubated with the drug for 72 h and harvested. Flow count beads (Beckman Coulter, Miami, FL) were added to the cell suspension, followed by propidium iodide staining and analysis using an Epics Elite flow cytometer (Beckman Coulter). The 50% cytotoxic concentration (CC50) was calculated from the cell counts and viability.

The effects of hexadecyloxypropyl-HPMPA (HDP-HPMPA), octadecyloxyethyl-HPMPA (ODE-HPMPA), oleyloxyethyl-HPMPA (OLE-HPMPA), and oleyloxypropyl-HPMPA (OLP-HPMPA) on HIV replication in infected MT-2 cells were assessed by p24 reduction (Table 1). Unmodified (S)-HPMPA was essentially inactive against HIV-1, as reported previously (3, 8, 13, 17), with an EC50 of 77 µM. Contrary to expectation, however, the alkoxyalkyl esters of (S)-HPMPA were active against HIV-1, and all exhibited EC50s in the low-nanomolar range. The most active compound was ODE-(S)-HPMPA, with an EC50 of 0.4 nM and a selectivity index of 75. HDP-(S)-HPMPA was less active, with an EC50 of 7 nM, but more selective, with a selectivity index of 143. Alkoxyalkyl esters of (S)-HPMPA were more cytotoxic than unmodified (S)-HPMPA. This is consistent with the results obtained previously with alkoxyalkyl esters of CDV, which also exhibited greater cytotoxicity and greater selectivity than CDV (4, 16, 20).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Antiviral activities and selectivities of alkoxyalkyl esters of (S)-HPMPA against HIVLAI

 
We also evaluated the activities of HDP-(S)-HPMPA and ODE-(S)-HPMPA against a panel of four drug-resistant HIV variants, including viruses resistant to AZT (4xAZT), lamivudine (M184V), tenofovir (K65R), and nevirapine (K103N). HDP-(S)-HPMPA and ODE-(S)-HPMPA retained nearly full antiviral activity against 4xAZT, M184V, and K103N. Significant resistance was noted with K65R, but the EC50s for HDP- and ODE-(S)-HPMPA were 0.16 and 0.003 µM, respectively, suggesting that the compounds could be clinically useful, since plasma levels of 1 to 2 µM are attainable in animal studies (J. Trahan and K. Y. Hostetler, unpublished data) (Table 2).


View this table:
[in this window]
[in a new window]
  		TABLE 2. Antiviral activities of HDP-(S)-HPMPA and ODE-(S)-HPMPA against HIVLAI and drug-resistant HIV variants

 
We reported previously that the CDV analog hexadecyloxypropyl-CDV (HDP-CDV) showed >100-fold increases in antiviral activity versus the unmodified CDV against cells infected with orthopoxviruses, cowpox virus, and vaccinia virus (4, 16, 19). The cellular uptake and anabolic metabolism of 14C-labeled CDV and HDP-CDV was evaluated in fibroblasts. HDP-CDV was taken up rapidly by MRC-5 human lung fibroblasts in vitro, but CDV uptake was much slower. Analysis of cellular metabolites showed that levels of CDV diphosphate, the active antiviral compound, were >100 times greater with HDP-CDV than with CDV (1). However, the degree of enhancement of antiviral activity does not always correlate with the increase in cellular uptake and conversion of HDP-CDV to CDV diphosphate. In various viruses of the herpesvirus group, increases in antiviral activity with HDP-CDV varied from 40- to >52,000-fold (21).

HDP-CDV seems to circumvent poor cellular uptake by rapid association with cellular membrane phospholipids, whereas CDV uptake proceeds via the slow process of fluid phase endocytosis (7). This may be, at least in part, the explanation for the enhanced activity of HDP-(S)-HPMPA in HIV-infected MT-2 cells While tenofovir and adefovir are chain terminators, the mechanism of action of HPMPA diphosphate against HIV reverse transcriptase or any other viral polymerase is not presently known.

In summary, esterification of (S)-HPMPA with long-chain alkoxyalkanols resulted in a 3- to 5-log increase in antiviral activity against HIV-1 infection in MT-2 cells versus unmodified HPMPA. HDP-(S)-HPMPA and ODE-(S)-HPMPA are also active against HIV variants which are resistant to AZT, lamivudine, nonnucleoside reverse transcriptase inhibitors, and tenofovir. Enhanced antiviral activity of HDP-(S)-HPMPA and ODE-(S)-HPMPA against human cytomegalovirus, murine cytomegalovirus, vaccinia virus, cowpox virus, and adenovirus (5, 12) and hepatitis B virus (B. Korba and K. Y. Hostetler, unpublished data) was also shown previously. Preliminary studies indicate that HDP-(S)-HPMPA and ODE-(S)-HPMPA are orally active against lethal vaccinia and cowpox challenge in mice (19) and are worthy of further evaluation as a possible broad-spectrum antiviral therapy for HIV-1 infection in humans.


   ACKNOWLEDGMENTS
 
This work was funded in part by grants from the National Institute of Allergy and Infectious Diseases (AI-29164 and AI-66499) and the U.S. Army, DAMD (17-01-2-0071).

K. Y. Hostetler has an equity interest in and serves as a consultant to Chimerix Inc. The terms of this arrangement have been reviewed and approved by the University of California, San Diego, in accordance with its conflict-of-interest policies.


   FOOTNOTES
 
* Corresponding author. Mailing address: Division of Infectious Disease, Department of Medicine, University of California, San Diego, Mail Code 0676, 9500 Gilman Drive, La Jolla, CA 92093-0676. Phone: (858) 552-8585, ext. 2616. Fax: (858) 534-6133. E-mail: khostetl{at}ucsd.edu. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Aldern, K. A., S. L. Ciesla, K. L. Winegarden, and K. Y. Hostetler. 2003. The increased antiviral activity of 1-O-hexadecyloxypropyl-cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 63:678-681.[Abstract/Free Full Text]
  2. Baker, R. O., M. Bray, and J. W. Huggins. 2003. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 57:13-23.[CrossRef][Medline]
  3. Balzarini, J., A. Holy, J. Jindrich, L. Naesens, R. Snoeck, D. Schols, and E. De Clercq. 1993. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethyoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother. 37:332-338.[Abstract/Free Full Text]
  4. Beadle, J. R., C. Hartline, K. A. Aldern, N. Rodriguez, E. Harden, E. R. Kern, and K. Y. Hostetler. 2002. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46:2381-2386.[Abstract/Free Full Text]
  5. Beadle, J. R., W. B. Wan, S. L. Ciesla, K. A. Keith, C. Hartline, E. R. Kern, and K. Y. Hostetler. 2006. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine (HPMPA) against cytomegalovirus and orthopoxviridiae. J. Med. Chem. 49:2010-2015.[CrossRef][Medline]
  6. Buller, R. M., G. Owens, J. Schriewer, L. Melman, J. R. Beadle, and K. Y. Hostetler. 2004. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318:474-481.[CrossRef][Medline]
  7. Connelly, M. C., B. L. Robbins, and A. Fridland. 1993. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. Biochem. Pharmacol. 46:1053-1057.[CrossRef][Medline]
  8. De Clercq, E. 1991. Chemotherapy of the acquired immune deficiency syndrome (AIDS): acyclic nucleoside phosphonate analogs. Int. J. Immunopharmacol. 13(Suppl. 1):91-98.[Medline]
  9. De Clercq, E., A. Holy, I. Rosenberg, T. Sakuma, J. Balzarini, and P. C. Maudgal. 1986. A novel selective broad-spectrum anti-DNA virus agent. Nature 323:464-467.[CrossRef][Medline]
  10. De Clercq, E., T. Sakuma, M. Baba, R. Pauwels, J. Balzarini, I. Rosenberg, et al. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8:261-272.[CrossRef][Medline]
  11. Hammond, J. L., D. Koontz, H. Z. Bazmi, J. R. Beadle, S. E. Hostetler, G. D. Kini, K. A. Aldern, D. D. Richman, and K. Y. Hostetler. 2001. Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside resistant human immunodeficiency virus type 1 and select for resistance mutations that reverse zidovudine resistance. Antimicrob. Agents Chemother. 45:1621-1628.[Abstract/Free Full Text]
  12. Hartline, C. B., K. M. Gustin, W. B. Wan, S. L. Ciesla, J. R. Beadle, K. Y. Hostetler, and E. R. Kern. 2005. Activity of ether lipid ester prodrugs of acyclic nucleoside phosphonates against adenovirus replication in vitro. J. Infect. Dis. 191:396-399.[CrossRef][Medline]
  13. Holy, A. 2003. Phosphonomethoxyalkyl analogs of nucleotides. Curr. Pharmaceut. Design 9:2567-2592.[CrossRef][Medline]
  14. Holy, A., I. Rosenberg, and K. Slama. 1987. Isomeric O-phosphonylmethyl derivatives of enantiomeric and racemic 9-(2,3-dihydroxypropyl)adenine. U.S. patent 4,659,825.
  15. Keith, K. A., M. J. M. Hitchcock, W. A. Lee, A. Holy, and E. R. Kern. 2003. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob. Agents Chemother. 47:2193-2198.[Abstract/Free Full Text]
  16. Kern, E. R., C. Hartline, E. Harden, K. Keith, N. Rodriguez, J. R. Beadle, and K. Y. Hostetler. 2002. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46:991-995.[Abstract/Free Full Text]
  17. Naesens, L., J. Balzarini, and E. De Clercq. 1995. The potential of acyclic nucleoside phosphonates as broad-spectrum antiviral agents. Postepy Biochemii 41:347-351.[Medline]
  18. Quenelle, D. C., D. J. Collins, K. Y. Hostetler, J. R. Beadle, W. B. Wan, and E. R. Kern. 2004. Oral treatment of cowpox and vaccinia infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48:404-412.[Abstract/Free Full Text]
  19. Quenelle, D. C., D. J. Collins, K. A. Keith, J. Trahan, J. R. Beadle, K. Y. Hostetler, and E. R. Kern. 2005. Effect of oral treatment with HDP-(S)-HPMPA or ODE-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Antiviral Res. 65:76, A81.
  20. Wan, W. B., J. R. Beadle, C. Hartline, E. R. Kern, S. L. Ciesla, N. Valiaeva, and K. Y. Hostetler. 2005. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 49:656-662.[Abstract/Free Full Text]
  21. Williams-Aziz, S. L., C. B. Hartline, E. A. Harden, S. M. Daily, M. N. Prichard, N. L. Kushner, J. R. Beadle, W. B. Wan, K. Y. Hostetler, and E. R. Kern. 2005. Comparative activity of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother. 49:3724-3733.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, August 2006, p. 2857-2859, Vol. 50, No. 8
0066-4804/06/$08.00+0     doi:10.1128/AAC.01223-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hostetler, K. Y.
Right arrow Articles by Beadle, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hostetler, K. Y.
Right arrow Articles by Beadle, J. R.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS